

DAFTAR PUSTAKA

- Adan, A., Kiraz, Y., & Baran, Y., 2016. Cell Proliferation and Cytotoxicity Assays. *Current pharmaceutical biotechnology*. 17(14):1213–1221.
- Akingbesote ND, Norman A, Zhu W, et al., 2022. A precision medicine approach to metabolic therapy for breast cancer in mice. *Commun Biol*. 5(1): 478.
- Alberto Preda, Fabrizio Montecucco, Federico Carbone, Giovanni G Camici, Thomas F Lüscher, Simon Kraler, Luca Liberale., 2024. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. *Cardiovascular Research*. 120: 443–460
- Al-Humaidi, R.B., Fayed, B., Shakartalla, S.B., Jagal, J., Jayakumar, M.N., Al Shareef, Z.M., et al., 2022. Optimum inhibition of MCF-7 breast cancer cells by efficient targeting of the macropinocytosis using optimized paclitaxel-loaded nanoparticles. *Life Sci*. 15:3
- Bardaweel S, Issa A., 2022. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy. *J Pharm Pharm Sci*. 25:253-265.
- Basak D, Gamez D, Deb S., 2023. SGLT2 Inhibitors as Potential Anticancer Agents. *Biomedicines*. 11(7):1867.
- Bioline Reagents Ltd. 2016. SensiFAST™ SYBR No-ROX One-Step Kit User Manual. London, UK: Bioline Reagents Ltd.
- Cancer Chemoprevention Research Center (CCRC), 2013. Protokol Uji Sitotoksik Metode MTT. Yogyakarta: Fakultas Farmasi, Universitas Gadjah Mada.
- Chang, W. T., Lin, Y. W., Ho, C. H., Chen, Z. C., Liu, P. Y., & Shih, J. Y. 2021. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. *Archives of toxicology*. 95(2):659–671
- Chen, D., Liu, X., Yang, Y., Yang, H., & Lu, P. 2015. Systematic synergy modeling: understanding drug synergy from a systems biology perspective. *BMC systems biology*. 9:56
- Chen, G., Liu, W., Yan, B., 2022. Breast Cancer MCF-7 Cell Spheroid Culture for Drug Discovery and Development. *J Cancer Ther*. 13(3):117-130.
- Chu J., Zhu Y., Liu Y., Sun L., Lv X., Wu Y., Hu P., Su F., Gong C., Song E., Liu B., Liu Q. 2015. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. *Oncotarget*. 6: 31944-31957
- Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. 2023. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. *International journal of molecular sciences*. 24(7):6834

- Comşa, Ş., Cîmpean, A. M., & Raica, M. 2015. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. *Anticancer research*. 35(6), 3147–3
- Dabour, M, George, M, Daniel, M. et al.2024. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review. *J Am Coll Cardiol CardioOnc*. 6(2): 159–182.
- Dawson, S.J., Makretsov, N., Blows, F.M., Driver, K.E., Provenzano, E., Le, Quesne, J., Baglietto, L., Severi, G., Giles, G.G., McLean, C.A., Callagy, G., Green, A.R., Ellis, I., Gelmon, K., Turashvili, G., Leung, S., Aparicio, S., Huntsman, D., Caldas, C., Pharoah, P., 2010. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *Br J Cancer*.103(5):668-75
- Dutka M, Bobiński R, Francuz T, et al., 2022. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives. *Cancers (Basel)*.14(23):5811.
- Fan, Y., Wang, J., Xu, Y., Wang, Y., Song, T., Liang, X., Jin, F., & Su, D. 2021. Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression. *Cell communication and signaling : CCS*, 19(1)
- Farrar MC, Jacobs TF.,2023. Tamoxifen. In: StatPearls [Internet].
- Favorgen Biotech Corp. 2015. FavorPrep™ Tri-RNA Reagent User Manual. Taiwan: Favorgen Biotech Corp.
- Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, et al., 2018. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. 5(2):77-106
- Funakoshi-Tago, M., Tago, K., Li, C., Hokimoto, S., & Tamura, H. 2020. Coffee decoction enhances tamoxifen proapoptotic activity on MCF-7 cells. *Scientific reports*.10(1).
- Gao, J.J., Swain, S.M., 2018. Luminal A Breast Cancer and Molecular Assays: A Review. *Oncologist*. 23(5):556-565. Montalto, F.I., De, Amicis, F., 2020. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. *Cells*. 9(12):2648.
- Garczorz W, Kosowska A, Francuz T. 2024. Antidiabetic Drugs in Breast Cancer Patients. *Cancers (Basel)*.16(2):299
- Ghayoumpour, N., & Ghafouri, H. 2025. Enhancing breast cancer treatment: Evaluating the efficacy of hyaluronic acid-coated tamoxifen-loaded solid lipid nanoparticles on MCF7 cells. *Human & experimental toxicology*.44.
- Gyimesi G, Pujol-Giménez J, Kanai Y, Hediger MA. 2020. Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors:

from molecular discovery to clinical application. *Pflugers Arch.* 472(9):1177-1206

Han, X., Liu, X., Zhao, X., Wang, X., Sun, Y., Qu, C., Liang, J., & Yang, B. 2023. Dapagliflozin ameliorates sepsis-induced heart injury by inhibiting cardiomyocyte apoptosis and electrical remodeling through the PI3K/Akt pathway. *European journal of pharmacology.* 955.

Hardwick, J.M., Soane, L., 2013. Multiple functions of BCL-2 family proteins. *Cold Spring Harb Perspect Biol.* 5(2): a008722.

Hasson, S. P., Rubinek, T., Ryvo, L., & Wolf, I. 2013. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway. *Breast care.* 8(4): 248–255.

Hu, R., Hilakivi-Clarke, L., & Clarke, R. 2015. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). *Oncology Letters.* 9: 1495-1501.

Huang, X., Guo, X., Yan, G., Zhang, Y., Yao, Y., Qiao, Y., Wang, D., Chen, G., Zhang, W., Tang, C., & Cao, F. 2022. Dapagliflozin Attenuates Contrast-induced Acute Kidney Injury by Regulating the HIF-1 α /HE4/NF- κ B Pathway. *Journal of cardiovascular pharmacology.* 79(6): 904–913.

Huang, X., Song, C., Zhang, J., Zhu, L., & Tang, H. 2023. Circular RNAs in breast cancer diagnosis, treatment and prognosis. *Oncology research.* 32(2): 241–249.

Hutcheson, I. R., Knowlden, J. M., Madden, T. A., Barrow, D., Gee, J. M., Wakeling, A. E., & Nicholson, R. I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. *Breast cancer research and treatment.* 81(1): 81–93.

Ignatov, T., Treeck, O., Kalinski, T., Ortmann, O., & Ignatov, A. 2020. GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients. *Archives of gynecology and obstetrics.* 301(2): 565–571.

Ishii, Y., Waxman, S., & Germain, D. 2008. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. *Cancer research.* 68(3): 852–860.

Jahani, Z., & Davoodi, J. 2022. Opposing effects of metformin mediated mTORC1 inhibition on IRES possessing anti-apoptotic proteins in breast cancer cell lines. *Biochemical and biophysical research communications.* 629: 71–77.

Jeffreys Sahar, Becker Therese, Khan sarah, Soon Patsy, Neubauer hans, Souza paul, Powter Branka. 2022. Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis. *Front. Endocrinol.* 13.

- Jirström, K., Stendahl, M., Rydén, L., Kronblad, A., Bendahl, P. O., Stål, O., & Landberg, G. 2005. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. *Cancer research*. 65(17): 8009–8016.
- Karim S, Alghanmi AN, Jamal M, et al. 2024. A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells. *Oncol Res*. 32(5): 817-830.
- Karzoon, A., Yerer, M.B. & Cumaoglu, A. 2025. Empagliflozin demonstrates cytotoxicity and synergy with tamoxifen in ER-positive breast cancer cells: anti-proliferative and anti-survival effects. *Naunyn-Schmiedeberg's Arch Pharmacol*. 398:781–798
- Kawiak, A., Kostecka, A., 2022. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. *Cancers*.14(2): 279
- Kementerian Kesehatan Republik Indonesia (Kemenkes RI), 2018. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara. Jakarta: Kementerian Kesehatan Republik Indonesia
- Kilker, R. L., Hartl, M. W., Rutherford, T. M., & Planas-Silva, M. D. 2004. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. *The Journal of steroid biochemistry and molecular biology*. 92(1-2): 63–71.
- Komatsu S., Nomiyama T., Numata T., Kawanami T., Hamaguchi Y., Iwaya C., Horikawa T., Fujimura-Tanaka Y., Hamanoue N., Motonaga R., et al. 2020. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. *Endocr. J*. 67:99–106.
- Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y. 2017. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma. *Med Sci Monit*. 1(23): 3737-3745.
- Kumar, U., Ardasheva, A., Mahmud, Z., Coombes, R.C., Yagüe, E., 2021. FOXA1 is a determinant of drug resistance in breast cancer cells. *Breast Cancer Res Treat*.186(2): 317-326.
- Lau KTK, Ng L, Wong JWH, Loong HHF, Chan WWL, Lee CH, Wong CKH. 2021. Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review. *Rev Endocr Metab Disord*. 22(4):1121-1136.
- Li, S., Garay, J.P., Tubbs, C.A. and Franco, H.L., 2021. CRISPR-based knock-in mutagenesis of the pioneer transcription factor FOXA1: optimization of strategies for multi-allelic proteins in cancer cells. *FEBS Open Bio*. 11(6):1537-1551.

- Li, W., Shi, X., Xu, Y., Wan, J., Wei, S., & Zhu, R. 2017. Tamoxifen promotes apoptosis and inhibits invasion in estrogen-positive breast cancer MCF-7 cells. *Molecular Medicine Reports*. 16: 478-484.
- Liberti, M. V., & Locasale, J. W. 2016. The Warburg Effect: How Does it Benefit Cancer Cells. *Trends in biochemical sciences*. 41(3): 211–218
- Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E. M., Francis, P. A., Gamal-Eldin, H., Gelmon, K., Geyer, C. E., Gnant, M., Guarneri, V., Gupta, S., Kim, S. B. 2024. ESMO Guidelines. *journal of the European Society for Medical Oncology*. 35(2): 159–182.
- Lucantoni, F., Salvucci, M., Düssmann, H., Lindner, A.U., Lambrechts, D., Prehn, J.H.M., 2021. BCL(X)L and BCL2 increase the metabolic fitness of breast cancer cells: a single-cell imaging study. *Cell Death Differ*. 28(5):1512-1531.
- Luis, C., Castaño-Guerrero, Y., Soares, R., Sales, G., & Fernandes, R. 2019. Avoiding the Interference of Doxorubicin with MTT Measurements on the MCF-7 Breast Cancer Cell Line. *Methods and Protocols*. 2(2): 29.
- Lundgren, K., Brown, M., Pineda, S. et al. 2012. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. *Breast Cancer Res*. 14: 57
- Mao, M., Hu, D., Yang, J., Chen, Y., Zhang, X., Shen, J., Teng, R., Zhou, J., & Wang, L. 2021. Regulation of tamoxifen sensitivity by the PLAC8/MAPK pathway axis is antagonized by curcumin-induced protein stability change. *Journal of molecular medicine*. 99(6):845–858.
- Marks, B.A., Pipia, I.M., Mukai, C. et al. 2023. GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1. *BMC Cancer*. 23: 138
- Marshal Agreno, Noer Faisal Darmi, Jufriady Ismy, Ferry Erdani, Imam Hidayat. 2022. Pengaruh Periode Penggunaan Tamoxifen Terhadap Kejadian Endometriosis Pada Penderita Kanker Payudara. *J Indon Med Assoc*. 71 (6)
- Menon G, Alkabban FM, Ferguson T. Breast Cancer. [Updated 2024 Feb 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
- Molina, L., Bustamante, F., Ortloff, A., Ramos, I., Ehrenfeld, P., & Figueroa, C. D. 2020. Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation. *Frontiers in endocrinology*. 11.
- Montalto, F.I., De, Amicis, F., 2020. Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. *Cells*. 9(12): 2648

- Motawi, T. K., Abdelazim, S. A., Darwish, H. A., Elbaz, E. M., & Shouman, S. A. 2016. Modulation of Tamoxifen Cytotoxicity by Caffeic Acid Phenethyl Ester in MCF-7 Breast Cancer Cells. *Oxidative medicine and cellular longevity*.
- Naeimzadeh, Y., Tajbakhsh, A., Nemati, M. & Fallahi, J. 2024. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies, *European Journal of Pharmacology*. 978.
- Okada, J., Yamada, E., Saito, T., Yokoo, H., Osaki, A., Shimoda, Y., Ozawa, A., Nakajima, Y., Pessin, J. E., Okada, S., & Yamada, M. 2020. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. *Molecules*. 25(3): 495.
- Orrantia, B.E., Anchondo, N.P., Acuña, L.E., et al., 2022. Subtypes of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer [Internet]. Brisbane (AU): Exon Publications
- Papadopoli, D., Uchenunu, O., Palia, R., Chekkal, N., Hulea, L., Topisirovic, I., Pollak, M., & St-Pierre, J. (2021). Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. *Neoplasia*. 23(4): 391–399.
- Pashayan, N., Antoniou, A.C., Ivanus, U. et al. 2020. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nat Rev Clin Oncol*. 17: 687–705.
- Purnama, SY. 2025. Efek pemberian tamoxifen citrate terhadap ekspresi mRNA GPER-1, SNAIL1 dan CDH1 pada lini sel kanker payudara MCF-7: Tinjauan terhadap penanda awal EMT [tesis]. Yogyakarta: Universitas Gadjah Mada
- Rahem, S.M., Epsi, N.J., Coffman, F.D., Mitrofanova, A., 2020. Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer. *EBioMedicine*. 61:103047.
- Rondón-Lagos, M., Villegas, V. E., Rangel, N., Sánchez, M. C., & Zaphiropoulos, P. G. 2016. Tamoxifen Resistance: Emerging Molecular Targets. *International journal of molecular sciences*. 17(8):1357.
- Sabaa, M., Sharawy, M. H., El-Sherbiny, M., Said, E., Salem, H. A., & Ibrahim, T.M. 2022. Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats. *Biomedicine & pharmacotherapy*. 155: 113675.
- Saheed, E.S., Aromolaran, R.F., Atoyebi, A.D. et al. 2024. Mechanism of the Warburg effect and its role in breast cancer immunotherapy. *Discov Med*. 1: 110 .
- Saito, T., Okada, S., Yamada, E., Shimoda, Y., Osaki, A., Tagaya, Y., Shibusawa, R., Okada, J., & Yamada, M. 2015. Effect of dapagliflozin on colon cancer cell [Rapid Communication]. *Endocrine journal*. 62(12):1133–1137

- Sa-Nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. 2017. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. *Toxicology and applied pharmacology*. 333:43–50
- Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., Cardoso, F., & ESMO Guidelines Committee. 2015. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology*. 26 (5): 8–30.
- Shen, J., He, Y., Li, S., & Chen, H. 2024. Crosstalk of methylation and tamoxifen in breast cancer (Review). *Molecular medicine reports*. 30(4)
- SMOBIO Technology, Inc. 2022. ExcelRT™ Reverse Transcription Kit User Manual. Taiwan: SMOBIO Technology
- Suiçmez, M., Namalır, G., & Özdil, H. 2023. In Vitro Evaluation of Cytotoxic and Antitumor Activities of The Tamoxifen and Doxorubicin Combination on MCF-7 and BT-474 Breast Cancer Cell Lines. *Journal of the Institute of Science and Technology*. 13(4):2997-3006
- Sun, J., Zhang, X., Wang, S., Chen, D., Shu, J., Chong, N., Wang, Q., & Xu, Y. 2024. Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway. *Diabetology & metabolic syndrome*. 16(1):38
- Sun, M., Sun, J., Sun, W., Li, X., Wang, Z., Sun, L., & Wang, Y. 2024. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential. *Frontiers in pharmacology*. 15.
- Turczyk, L., Kitowska, K., Mieszkowska, M., Mieczkowski, K., Czaplinska, D., Piasecka, D., Kordek, R., Skladanowski, A. C., Potemski, P., Romanska, H. M., & Sadej, R. 2017. FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ER α -Positive Breast Cancer Cells. *Neoplasia*. 19(10): 791–804
- Vinuesa-Pitarch, E., Ortega-Álvarez, D., & Rodilla, V. 2021. How Lineage Tracing Studies Can Unveil Tumor Heterogeneity in Breast Cancer. *Biomedicines*, 10(1): 3
- Wang, J., Zhou, Z., 2023. Estrogen-dependent activation of NCOA3 couples with p300 and NF- κ B to mediate antiapoptotic genes in ER-positive breast cancer cells. *Discov Oncol*. 14(1):28.
- Wang, W., Fan, J., Yang, X., Fürer-Galban, S., Lopez de Silanes, I., von Kobbe, C., Guo, J., Georas, S. N., Foulfelle, F., Hardie, D. G., Carling, D., & Gorospe, M. 2002. AMP-activated kinase regulates cytoplasmic HuR. *Molecular and cellular biology*. 22(10): 3425–3436.
- Widiana, I., Ketut, Hendry Irawan., 2020. Clinical and subtypes of breast cancer in Indonesia. *Asian Pacific Journal of Cancer Care*. 5(4): 281-285

- Wong, G. L., Manore, S. G., Doheny, D. L., & Lo, H. W. 2022. STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges. *Seminars in cancer biology*. 86(Pt 3): 84–106.
- Wright EM, Ghezzi C, Loo DDF. 2017. Novel and Unexpected Functions of SGLTs. *Physiology (Bethesda)*. 32(6):435-443.
- Wu, W., Wang, Y., Xie, J., & Fan, S. 2023. Empagliflozin: a potential anticancer drug. *Discover oncology*. 14(1): 127.
- Wu, X., Gardashova, G., Lan, L., Han, S., Zhong, C., Marquez, R. T., Wei, L., Wood, S., Roy, S., Gowthaman, R., Karanicolas, J., Gao, F. P., Dixon, D. A., Welch, D. R., Li, L., Ji, M., Aubé, J., & Xu, L. 2020. Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis. *Communications biology*. 3(1): 193.
- Ye, L., Lin, C., Wang, X., Li, Q., Li, Y., Wang, M., Zhao, Z., Wu, X., Shi, D., Xiao, Y. and Ren, L., 2019. Epigenetic silencing of SALL 2 confers tamoxifen resistance in breast cancer. *EMBO Molecular Medicine*. 11(12).
- Yi, J., Du, J., Chen, X., Nie, R. C., Hu, G. S., Wang, L., Zhang, Y. Y., Chen, S., Wen, X. S., Luo, D. X., He, H., & Liu, W. 2025. A circRNA-mRNA pairing mechanism regulates tumor growth and endocrine therapy resistance in ER-positive breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*. 122(8).
- Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S.2023. Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control. *Int J Mol Sci*. 24(7):6039.
- Yuan, J., Dong, X., Yap, J. *et al*. 2020. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. *J Hematol Oncol*. 13: 113.
- Zaibi, N., Li, P., & Xu, S. Z.2021. Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells. *PloS one*. 16(2)
- Zhang, P., Cao, M., Liu, Y. *et al*. 2012. PDGF-induced airway smooth muscle proliferation is associated with Human antigen R activation and could be weakened by AMPK activation. *Mol Biol Rep*. 39: 5819–5829.
- Zhou, J., Zhu, J., Yu, S. J., Ma, H. L., Chen, J., Ding, X. F., Chen, G., Liang, Y., & Zhang, Q. 2020. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. *Biomedicine & pharmacotherapy*. 132.